57results about How to "Solve clinical problems" patented technology

The invention relates to an atorvastatin calcium dried suspension and a preparation method thereof. The atorvastatin calcium dried suspension comprises the following components in portion by weight: 1 to 10 portions of atorvastatin calcium, 10 to 95 portions of filling agent, 1 to 30 portions of suspension and / or suspending agent, 2 to 40 portions of flavoring agent, and 0.2 to 2.0 portions of lubricating agent. The atorvastatin calcium dried suspension has the advantages of high dispersity, even distribution, quick absorption, high bioavailability, good adaptability, good mouthfeel, stability and the like. The atorvastatin calcium dried suspension can be applied to regulation of blood fat.

The invention discloses a berberine azole compound shown in general formulas such as I-IV, and a pharmaceutically acceptable salt thereof, and also discloses a preparation method of the compound, which comprises the following steps that: a compound VI and an azole compound HIm or 1H-2-mercaptobenzimidazole are reacted to obtain an intermediate VII or VIII, and then the obtained intermediate is reacted with a compound V to obtain the berberine azole compound shown in general formulas such as I or II; and the compound V and a compound IX or XI are reacted to obtain an intermediate X or XII, and then the obtained intermediate is reacted with the azole compound Him to obtain the berberine azole compound shown in general formulas such as III or IV. The berberine azole compound has a certain inhibitory activity on Gram-positive bacteria, Gram-negative bacteria and fungi, the anti-bacterial activity of part of the compounds is equal to or even stronger than that of chloramphenicol or norfloxacin, the antifungal activity of part of the compounds is equal to or even stronger than that of fluconazole, and the berberine azole compound can be used for preparing anti-microbial drugs.

A stapling instrument for the posterolateral side of the anastomosis of the tubular esophagus and the stomach, which includes a tube extending into the front end of the tube, a stapling part capable of forming a "mouth"-shaped suture structure with an opening, and an operating part extending into the rear end of the tube; The stapling part includes the nail cartridge integrally connected with the extension tube, the pressing structure for pressing the nails out of the magazine, and the moving block that drives the pressing structure to move down and is moved by the operation of the operating part; the reciprocating motion of the moving block drives the pressing structure to repeat Pressing down and returning, the longitudinal direction of the staple cartridge is consistent with the longitudinal direction of the insertion tube, the two sides of the front end of the staple cartridge are provided with blocking plates to block the staples, and the inner side of the blocking plate is provided with an opening for the staples to move down and out of the staple cartridge; the insertion tube Corresponding to the front section of the rear wall of the opening and the lower part of the staple cartridge, a gap is set; a "T"-shaped support is set in the middle of the front of the staple cartridge, and the "T"-shaped support includes a beam one and a longitudinal support beam; The transverse bar of the T-shaped support is bent to form a "mouth"-shaped suture structure to suture the tissue.

The invention provides a flavone imidazole compound or pharmacologically acceptable salt thereof. General formula of the flavone imidazole compound is a general formula I, a general formula II or a general formula III, wherein R1 is selected from hydrogen, alkyl or hydroxy; R2 is selected from hydrogen, alkyl or hydroxyl; R3 is selected from hydrogen, alkyl or hydroxyl; R4 is selected from hydrogen, alkyl and substituted aryl; R5 is selected from hydrogen or normal-butyl; R6 is selected from hydrogen or chlorine. The invention also provides a preparation method of the flavone imidazole compound. After indicating by active detection results of in-vitro PTP1B (protein-tyrosine-phosphatase 1B), the synthesized flavone imidazole compound has certain inhibiting action on PTP1B; the basic theoretical basis is provided for developing of Type 2 diabetic mellitus drugs using the PTP1B as a target. The flavone imidazole compound has the advantages that the synthesizing route is short, the preparation method is simple, the obtaining of raw materials is easy, and the cost is low; the flavone imidazole compound is expected to provide more efficient and safe candidate drugs for treating the Type 2 diabetic mellitus, and is favorable for solving the problem of clinical treatment.